Healthcare Remains Steady As Market Approaches A Key LevelThe market is approaching a key technical level.Healthcare has relatively outperformed the market and has been consolidating.Biotechs found a bottom and are
Biotechs have sold off this year along with the broader market. Declines have been more pronounced than prior pullbacks. However, healthcare continues to outperform.Federal Reserve's interest rate policy will continue
Healthcare is relatively well-positioned as a defensive sector in a volatile market environment compared to the broader market.Favorable trends to continue boosting healthcare spending.Anti-viral data to begin providing hope and
Cassava Sciences has encountered serious allegations in the citizen's petition and other discrepancies that were subsequently uncovered.The allegations do not provide a concrete and relevant connection to data manipulation.FDA will
Prothena has developed broad expertise in removing plaques across different pathologies.FDA's acceptance of amyloid plaque reduction as a sufficient secondary endpoint for an accelerated approval de-risks multiple smallcap biotechs and
Biotechs are ready to march forcefully higher after a lengthy consolidation.Approval of Biogen's Alzheimer's treatment delivers a bonanza for neurodegenerative-focused companies and the overall biotech sectorThe lower bar set for
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act.Biotechs face an important FDA decision on approval of an Alzheimer's treatment.Oncology companies get ready to
Healthcare has been lagging the market, but that is now changing.As biotechs consolidate, other healthcare industry groups are powering the sector to a breakout.Medical Devices and Services are poised to
Biotech stocks remain under pressure due to fear of persistently rising interest rates.Neurology is a complex area of biotech with great promise and significant challenges.New approaches are broadening out the
Healthcare lagged the broader market last year, but that can change this year.A cyclical upturn as the pandemic abates and pent-up demand can boost healthcare.Best positioned are industry groups within
As the pandemic resurges, early vaccine trials are reaching the home stretch.Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments.Healthcare
Biotech is one of the rare industries whose prospects have improved as the year has progressed.A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates
Stocks plunge into a bear market as the viral outbreak threatens to devastate the economy.Healthcare has performed relatively better than the broader market which already has plunged over 30%.The healthcare
Last week, the enormity of the risk for healthcare diminished and investors reacted favorably.Healthcare lags the broader market quite significantly, and specifically, biotechs and pharmaceuticals lag even more so.We continue
Healthcare has been affected by the growing thrust towards regulation to reduce costs. Biotech and pharmaceutical valuations have been hurt as efforts to control drug prices intensify. Improving risk appetite
Biotech indexes have remained subdued as the broader market has rallied.The broader healthcare sector and biopharma industries, in particular, remain under regulatory duress just as they have been for some
American Society of Clinical Oncology (ASCO) annual event to provide some cheer to biotechs. Healthcare remains a sector under regulatory stress and in political cross sight.Broader market buffeted by trade
Biotech stocks and the broader healthcare sector remain under pressure.Promising opportunities exist in the small-cap and mid-cap segments.Gene therapy remains the emerging scientific frontier in biotech.3 promising small-cap gene therapy
2018 was a harder year than envisioned, even though second-half turbulence was somewhat anticipated
The biotechnology sector provided opportunities for attractive returns during 2018 although the late-year decline rapidly
The biotech stocks plunge along with the broader market, as the smallcap and midcap biotech stocks retreat -17%.
The larger cap biotechs and pharmaceutical companies are performing relatively much better.
Sharp market correction triggered by interest rate concerns creates opportunities
Market transitions into a more typical rally and pullback mode, with a continued firm uptrend
Biotech stocks are experiencing
July 26, 2017
FDA's new focus on accelerating drug approvals creates a valuation enhancing environment
Sentiment change with the approval of innovative life-saving drug class targeting cancer
Earnings season to
June 8, 2017
A possible "Comey Rally"
Favorable market environment for Biotechs
Positive news flow from ASCO
Potential catalysts - M&A, broader market advance, and health care policy clarity
February 09, 2017
Biotechs and pharmas remain under the cloud of uncertain policy
But recent developments increase confidence on the regulatory front
Sufficient biotech sector drivers now exist to create
January 24, 2017
Trump indicts the industry on "getting away with murder."
Pharmaceutical industry shows early signs of a shift towards self-regulation.
Innovation can be spurred by acquisitions.
January 11, 2017
Biotechnology sector was one of the worst performing sectors in 2016.
Political uncertainty has diminished but is still impairing investor confidence
Signs are present for the sector to
January 10, 2017
The Biotechnology sector's investment performance suffered last year with an over -21% decline. But don't let that dissuade you from joining drugmaker companies. According to a recent Bloomberg Pay
SEPTEMBER 29, 2016
Chair Janet Yellen delivers an unchanged monetary policy soothing the market.
Hillary Clinton appears to regain her footing in the presidential elections soothing global markets.
The biotechnology sector performed strongly during March and April.
Some sector-specific and market-related factors are clouding the positive narrative of the Biotechnology sector.
Even though near-term caution is advisable,